Novartis AG (NVS)
101.14
-0.95
(-0.93%)
USD |
NYSE |
Sep 22, 16:00
101.00
-0.14
(-0.14%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 209.18B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 36.84% |
| Valuation | |
| PE Ratio | 28.17 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.075 |
| Price to Book Value | 4.035 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 3.499 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.512 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 25.99% |
Profile
| Novartis develops and manufactures healthcare products through two business segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 24, 2023 |
| Last Earnings Release | Jul. 18, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 09, 2023 |
Ratings
Profile
| Novartis develops and manufactures healthcare products through two business segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue. |
| URL | https://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | N/A |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Equity Style | Large Cap/Blend |
| Next Earnings Release | Oct. 24, 2023 |
| Last Earnings Release | Jul. 18, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 09, 2023 |